South Korean company buys CDMO AMPAC

AMPACplantPetersburgVA
This plant in Petersburg, Virginia, is one of four that South Korea's SK Holdings has acquired in a deal to buy CDMO AMPAC. (SK Holdings)

South Korean investment firm SK Holdings got a start in contract manufacturing last year by snatching up a discarded Big Pharma plant in Europe. Now it has made a move on the U.S. with a deal to buy AMPAC, a contract manufacturer which makes APIs for controlled substances, among other things.

The two companies announced the deal on Thursday but not the terms. SK said the acquisition gives it not only a U.S. base but also a well-positioned U.S. manufacturing network with facilities on three coasts. AMPAC Fine Chemicals (AFC) has plants in Rancho Cordova and El Dorado Hills, California; La Porte, Texas; and Petersburg, Virginia.

"AFC's development and manufacturing capabilities and outstanding regulatory track record, evidenced by the fact that the California plant is utilized by the FDA as a training site, are an excellent complement to SK," CEO Dong-Hyun Jang said in a statement.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Last year, SK Biotek celebrated being the first South Korean drug company to set up operations in Ireland at the API plant in Swords it acquired from Bristol-Myers Squibb. It took over the 360 employees who worked there and got a contract to continue to produce some products for Bristol-Myers.

RELATED: Bristol-Myers selling Ireland plant to South Korean company with large aspirations

The deal gave SK Holdings, which had 2016 revenues exceeding $120 billion, its start in contract manufacturing, a field it sees as feeding its growth. SK pointed out that the CDMO industry has been growing at about 16% the last several years, while AMPAC has racked up 15% annual growth.  

Read more on

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.